The Break Up Big Medicine Act prohibits any single person or corporate group from simultaneously owning (1) an insurance company and a pharmacy benefit manager (PBM); or (2) a prescription drug or medical device wholesaler and a medical provider or management services organization (MSO). Entities in violation must divest either their upstream or downstream businesses within one year of enactment.
The Federal Trade Commission (FTC) and the Department of Justice (DOJ) share enforcement authority, and the statute creates a private right of action and parens patriae authority for state attorneys general.
This is a structural remedy aimed at vertical conflicts: it targets combinations the sponsors say allow self‑preferencing, transfer‑pricing to evade medical loss ratio limits, and incentives to steer prescribing or referrals. The bill builds a fast, mandatory divestiture regime with monetary penalties (a monthly escrow of 10 percent of profits for noncompliant firms), trustee authority to sell assets, reporting under Clayton Act section 7A, and a disgorgement fund administered by the FTC for harmed communities.
For companies, investors, and regulators, the Act realigns the M&A and compliance landscape for insurers, PBMs, wholesalers, provider groups and MSOs.
At a Glance
What It Does
The bill makes it unlawful for a person to own both (A) an insurer and a PBM that serves that insurer, or (B) a drug/device wholesaler and a provider or MSO; violators must divest one side of the business within one year. The FTC and DOJ share jurisdiction to enforce the prohibition, can require escrow of profits for missed milestones, and may appoint trustees to carry out divestitures.
Who It Affects
Large vertically integrated health platforms that combine health plans, PBMs, wholesalers, pharmacies, physician practices or MSOs; private equity owners and parent companies with cross‑sector portfolios; hospitals, specialty clinics and MSOs that could be divested; and state and federal antitrust enforcers.
Why It Matters
The Act is a rare statutory structural-separation remedy, not a case-by-case antitrust inquiry — it obligates divestiture on a statutory schedule and creates new private enforcement tools. That changes how buyers, sellers, and regulators will evaluate vertical deals and may require reorganizations of existing national health conglomerates.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The core command of the bill is simple and blunt: a single corporate owner may not simultaneously control certain upstream distribution or financing functions and downstream medical service providers. Practically, that means if a parent owns an insurer and a PBM, it must sell either the insurer/PBM side or its provider/MSO holdings; similarly, a parent that owns a national drug or device wholesaler must divest either the wholesaler or any providers/MSOs it controls.
The statute defines the covered entities broadly, listing examples of providers (pharmacies, physician practices, ambulatory surgery centers, hospitals, post‑acute providers) and detailing what counts as an MSO (payroll, billing, payer contracting, IT, scheduling and other non‑medical administrative services).
Enforcement sits with the FTC and DOJ’s Antitrust Division, jointly or separately. Within 30 days of enactment the agencies must issue guidance that sets milestone schedules for the one‑year divestiture window.
If a firm misses milestones, the agency may require a monthly transfer of 10 percent of the firm’s profits into escrow; those funds revert to the firm if divestiture completes on time or are deposited into an FTC‑administered fund if the deadline passes. If divestiture still does not occur, the statute authorizes appointment of a divestiture trustee who can sell the relevant assets and requires reporting of divestitures under Clayton Act section 7A (without regard to typical 7A thresholds), with tolling of the one‑year clock during any Clayton Act waiting period.The Act also creates multiple private enforcement routes.
Federal actors and state attorneys general may sue in federal court; residents may bring private actions in state or federal court for damages and equitable relief. A prevailing private plaintiff can recover treble damages, attorneys’ fees and costs.
Courts must order cease‑and‑desist relief, disgorge revenues generated by the offending affiliate and may order additional equitable remedies. The FTC must promulgate implementing rules and provide quarterly compliance reports to Congress.Taken together, the bill is designed to be both prophylactic and coercive: it prevents future vertical ownership structures by operation of law and compels undoing of current integrations through mandatory divestiture, monetary deterrents, trustee sales and broad private litigation exposure.
Several technical provisions — the escrow mechanism, trustee authority, deposit of disgorged funds into a statutory FTC fund, and mandatory 7A reporting — show the bill’s intent to accelerate unwinding of covered combinations.
The Five Things You Need to Know
The Act gives violators one year to divest either the upstream (insurer/PBM or wholesaler) or downstream (provider/MSO) assets, subject to tolling during any Clayton Act section 7A waiting period.
If a firm misses divestment milestones, the FTC or DOJ may require a monthly transfer equal to 10% of the firm’s profits into escrow until divestiture occurs; those funds go to an FTC‑administered fund if divestiture is not completed by the statutory deadline.
The bill creates a private right of action allowing individuals to sue for damages, with courts able to award treble damages, attorneys’ fees, and equitable relief, and it allows state attorneys general to sue as parens patriae.
All required divestitures must be reported under Clayton Act section 7A “without respect to” the usual size thresholds, and the FTC/DOJ will review both the divestiture and any subsequent purchaser for competitive and public‑interest effects.
If divestiture does not occur, the statute authorizes appointment of a divestiture trustee with authority to sell assets, and mandates that court orders require disgorgement of revenues obtained from the divested affiliate for the violation period.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the Act its popular name, the “Break Up Big Medicine Act.” This is purely formal but signals the bill’s focus on structural remedies for vertical integration in health care.
Findings
Summarizes Congress’s factual predicates: concentration among insurers, PBMs and wholesalers, employment of physicians by insurers, and vertical integration creating incentives to steer care and hide profits. Practically, these findings set the legislative rationale that interstate commerce is implicated and support the statutory divestiture mandate rather than a case‑by‑case antitrust standard.
Core prohibitions and mandatory divestiture
Makes it unlawful for a person to own both (1) a provider or MSO and an insurer plus PBM, or (2) a provider or MSO and a prescription drug/medical device wholesaler. Anyone in that position at enactment has one year to divest either the provider/MSO side or the insurer/PBM/wholesaler side. The practical implication is an immediate re‑organization requirement for any large conglomerate that crosses those lines; transactional planning and valuation issues will be front and center as sellers decide which assets to keep or shed.
Enforcement by FTC and DOJ, escrow penalty and trustee authority
Grants joint or separate jurisdiction to the FTC and the Assistant Attorney General for Antitrust to enforce the divestiture rules. Agencies must issue guidance within 30 days laying out milestones. For missed milestones, the agencies may force monthly transfers of 10 percent of the firm’s profits into escrow; if divestiture ultimately fails, those funds go to the FTC fund. The provision also authorizes appointment of a divestiture trustee who can sell assets if the owner fails to divest, shifting the burden of completing sales from the target owner to a court‑appointed fiduciary.
Civil enforcement and private rights of action
Permits the HHS Inspector General, DOJ Antitrust, the FTC, or state attorneys general to sue in federal court for violations, and gives individuals a private cause of action in state or federal court with treble damages, fees, and equitable relief. Courts must order cease‑and‑desist relief, divestiture and disgorgement of revenues obtained during the violation. This multiplies enforcement vectors and increases litigation risk for alleged violators — private plaintiffs may seek damages while public enforcers pursue divestiture and equitable remedies.
Clayton Act reporting, tolling and post‑divestiture review
Requires reporting of required divestitures under Clayton Act section 7A without regard to usual size thresholds, meaning even transactions below Hart‑Scott‑Rodino thresholds must be submitted. The one‑year divestiture clock is tolled during any waiting period under section 7A. The FTC and DOJ must review the competitive, financial viability and public‑interest effects of both the divestiture itself and any subsequent acquisition of the divested entity, giving agencies a continuing role after the sale.
Rulemaking and reporting obligations
Directs the FTC to issue rules to implement the statute and requires quarterly compliance reports from the FTC Chair and DOJ Antitrust head to Congress. Agencies cannot use rulemaking to reduce statutory obligations. This creates a dual pathway: immediate statutory obligations plus agency rulemaking to flesh out operational details, which will be crucial for market participants trying to comply.
Definitions
Provides broad, transactionally important definitions for key terms: PBM (explicit list of PBM activities), provider (taxonomy‑coded entities), MSO (wide list of administrative services), prescription drug/device wholesalers, and wholesale distribution (with enumerated exceptions). The definitions will determine the statute’s reach — for instance, the PBM definition is activity‑based and can capture third‑party administrators that perform core PBM functions even if they do not self‑identify as PBMs.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Independent physicians and small provider groups — forced divestitures could return ownership to standalone or local buyers, reducing incentives to steer referrals or code to maximize insurer revenue.
- Independent community pharmacies and specialty clinics — the breakup of PBM/pharmacy or wholesaler/provider verticals could restore negotiated leverage and reduce affiliated steering to in‑network, corporate pharmacies.
- Competing payers, PBMs and wholesalers — removal of integrated rivals may lower barriers to entry and permit more neutral formulary and network decisions, improving competition in purchasing and contracting.
Who Bears the Cost
- Integrated health conglomerates and their shareholders — they face mandated asset sales, potential loss of synergies, valuation discounts, and exposure to treble‑damages litigation.
- Private equity owners and strategic acquirers — portfolios that span insurers, PBMs, wholesalers and providers may be forced into rapid divestitures, complicating exit strategies and raising transaction costs.
- Regulators and courts — the FTC, DOJ and federal courts will need resources and technical expertise to supervise large, complex divestitures and to value and police escrow and disgorgement schemes.
Key Issues
The Core Tension
The central dilemma is the classic antitrust trade‑off: the bill seeks to eliminate conflicts of interest and self‑preferencing by structurally separating integrated health firms, but in doing so it compels the unwinding of vertically integrated arrangements that may deliver efficiency gains (care coordination, centralized IT, supply‑chain scale). Policymakers and courts will have to decide whether the harms from vertical conflicts outweigh the potential loss of integration benefits — a judgment the statute attempts to resolve by mandating breakup rather than leaving evaluation to case‑by‑case antitrust analysis.
The bill raises a series of implementation and legal challenges. First, the functional definitions — particularly of “management services organization,” “provider,” and the activity‑based PBM definition — are broad and will generate litigation over scope.
Firms may litigate whether an entity’s activity crosses the statutory line or whether ownership is “direct or indirect” under the Sherman Act definition. Second, forced divestiture of highly integrated, national operations is operationally difficult: separating shared IT, payer contracts, real estate, workforce arrangements, and third‑party vendor agreements can be costly and may harm care continuity if not carefully managed.
The statute contemplates trustee sales, but trustees will face the same buyers’ market and valuation challenges as sellers.
Third, the enforcement design creates potential circumvention and administrative burden. The 10% monthly escrow penalty targets profits, but the bill does not define the accounting period, profit measure, or treatment of intercompany transfer pricing — all issues that could produce disputes over escrow amounts.
The requirement to report divestitures under section 7A “without respect to” thresholds accelerates agency review but also imports Hart‑Scott‑Rodino procedural timing into the divestiture schedule, requiring coordination that the bill only partially addresses. Finally, the statute forces a policy trade‑off: structural separation reduces conflicts but risks eliminating productive vertical integration benefits such as care coordination, integrated data platforms, and supply‑chain efficiencies; agencies and courts will be asked to balance these competing effects when reviewing sales and purchasers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.